Follow the people · Insider
Nicholas Donoghoe
Nicholas Donoghoe files insider transactions with the SEC as an evp, chief bus/strat officer of AbbVie (ABBV). We hold 1 disclosed purchase or sale filed since 4 January 2019, 1 of them in the last 90 days.
- Files forABBV
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure18 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 2 January 2019 — 14 August 2026EVP, Chief Bus/Strat Officer · AbbVie (ABBV)38 Form 4 lines · source: SEC Form 4
Everything they disclosed
38 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 32,710 shares of AbbVieSEC Form 418 August 2026Common Stock, $0.01 par value · traded 14 August 2026 · filed 18 August 2026
- ▼ sold on the open market 32,710 shares of AbbVieSEC Form 418 August 2026Common Stock, $0.01 par value · traded 14 August 2026 · filed 18 August 2026
- exercised options over 32,710 shares of AbbVie (a derivative holding)SEC Form 418 August 2026Option (Right to buy) · traded 14 August 2026 · filed 18 August 2026
- had shares withheld for tax on 12,874 shares of AbbVieSEC Form 43 March 2026Common Stock, $0.01 par value · traded 27 February 2026 · filed 3 March 2026
- had shares withheld for tax on 12,874 shares of AbbVieSEC Form 43 March 2026Common Stock, $0.01 par value · traded 27 February 2026 · filed 3 March 2026
- was granted 13,031 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 4,632 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 5,172 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 20,312 shares of AbbVie (a derivative holding)SEC Form 420 February 2026Option (Right to buy) · traded 18 February 2026 · filed 20 February 2026
- was granted 6,222 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 20,312 shares of AbbVie (a derivative holding)SEC Form 420 February 2026Option (Right to buy) · traded 18 February 2026 · filed 20 February 2026
- was granted 13,031 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 4,632 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 5,172 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- was granted 6,222 shares of AbbVieSEC Form 420 February 2026Common Stock, $0.01 par value · traded 18 February 2026 · filed 20 February 2026
- ▼ sold on the open market 3,234 shares of AbbVieSEC Form 47 August 2025Common Stock, $0.01 par value · traded 5 August 2025 · filed 7 August 2025
- ▼ sold on the open market 10,061 shares of AbbVieSEC Form 47 August 2025Common Stock, $0.01 par value · traded 5 August 2025 · filed 7 August 2025
- had shares withheld for tax on 11,230 shares of AbbVieSEC Form 44 March 2025Common Stock, $0.01 par value · traded 28 February 2025 · filed 4 March 2025
- was granted 23,437 shares of AbbVie (a derivative holding)SEC Form 418 February 2025Option (Right to buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 11,017 shares of AbbVieSEC Form 418 February 2025Common Stock, $0.01 par value · traded 13 February 2025 · filed 18 February 2025
- was granted 4,520 shares of AbbVieSEC Form 418 February 2025Common Stock, $0.01 par value · traded 13 February 2025 · filed 18 February 2025
- was granted 4,634 shares of AbbVieSEC Form 418 February 2025Common Stock, $0.01 par value · traded 13 February 2025 · filed 18 February 2025
- was granted 5,174 shares of AbbVieSEC Form 418 February 2025Common Stock, $0.01 par value · traded 13 February 2025 · filed 18 February 2025
- ▼ sold on the open market 21,082 shares of AbbVieSEC Form 422 March 2024Common Stock, $0.01 par value · traded 20 March 2024 · filed 22 March 2024
- had shares withheld for tax on 16,771 shares of AbbVieSEC Form 41 March 2024Common Stock, $0.01 par value · traded 28 February 2024 · filed 1 March 2024
- was granted 21,433 shares of AbbVie (a derivative holding)SEC Form 420 February 2024Option (Right to buy) · traded 15 February 2024 · filed 20 February 2024
- was granted 22,657 shares of AbbVieSEC Form 420 February 2024Common Stock, $0.01 par value · traded 15 February 2024 · filed 20 February 2024
- was granted 6,042 shares of AbbVieSEC Form 420 February 2024Common Stock, $0.01 par value · traded 15 February 2024 · filed 20 February 2024
- was granted 4,520 shares of AbbVieSEC Form 420 February 2024Common Stock, $0.01 par value · traded 15 February 2024 · filed 20 February 2024
- was granted 4,634 shares of AbbVieSEC Form 420 February 2024Common Stock, $0.01 par value · traded 15 February 2024 · filed 20 February 2024
- ▼ sold on the open market 2,912 shares of AbbVieSEC Form 428 December 2023Common Stock, $0.01 par value · traded 26 December 2023 · filed 28 December 2023
- had shares withheld for tax on 2,355 shares of AbbVieSEC Form 43 March 2020Common Stock, $0.01 par value · traded 28 February 2020 · filed 3 March 2020
- was granted 72,013 shares of AbbVie (a derivative holding)SEC Form 424 February 2020Option (right to buy) · traded 20 February 2020 · filed 24 February 2020
- was granted 5,316 shares of AbbVieSEC Form 424 February 2020Common Stock, $0.01 par value · traded 20 February 2020 · filed 24 February 2020
- had shares withheld for tax on 902 shares of AbbVieSEC Form 46 January 2020Common stock, $0.01 par value · traded 2 January 2020 · filed 6 January 2020
- ▲ bought on the open market 7,525 shares of AbbVieSEC Form 430 August 2019Common stock, $0.01 par value · traded 29 August 2019 · filed 30 August 2019
- was granted 32,710 shares of AbbVie (a derivative holding)SEC Form 422 February 2019Option (right to buy) · traded 21 February 2019 · filed 22 February 2019
- was granted 5,565 shares of AbbVieSEC Form 44 January 2019Common Stock, $0.01 par value · traded 2 January 2019 · filed 4 January 2019
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.